Talazoparib,Enzalutamide
Pfizer,Astellas
['brca', 'crpc', 'pcsm', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
w/o os benefit for non-hrr, knowing the tox (30% incr in trgr3-4), and seeing in talapro that 2 pts in the parpi arm developed mds/leukemia, is there a rationale to use these drugs in 1l/2l non-hrr/nonbrca mcrpc? #gu23 #pcsm 
Chief, Manhattan Service, @MSK_RadOnc; GU and HN cancers; hubs and dad to 3; MD(@YaleMed) MPH (@HarvardSPH) MSL (@NorthwesternMSL) 🏳️‍🌈